A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Required: PD-L1 (CD274) expression ≥ 1% (≥ 1%)

PD-L1 expression ≥ 1%

Excluded: EGFR genetic alteration that has a targeted therapy in 1L as per local SoC

1L NSCLC participants with genetic alteration such as EGFR that has a targeted therapy in 1L as per local SoC

Must have received: standard of care

who have received adequate SoC

Must have received: — metastatic

Have received at least one prior regimen in metastatic setting (2L+ NSCLC)

Must have received: — none

Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%

Cannot have received: anti-TIGIT therapy

Previous treatment with anti-TIGIT therapy